Lyndsay Willmott

1.1k total citations
36 papers, 381 citations indexed

About

Lyndsay Willmott is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Lyndsay Willmott has authored 36 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Obstetrics and Gynecology, 13 papers in Reproductive Medicine and 10 papers in Oncology. Recurrent topics in Lyndsay Willmott's work include Endometrial and Cervical Cancer Treatments (22 papers), Ovarian cancer diagnosis and treatment (12 papers) and Cancer Genomics and Diagnostics (5 papers). Lyndsay Willmott is often cited by papers focused on Endometrial and Cervical Cancer Treatments (22 papers), Ovarian cancer diagnosis and treatment (12 papers) and Cancer Genomics and Diagnostics (5 papers). Lyndsay Willmott collaborates with scholars based in United States, Italy and Denmark. Lyndsay Willmott's co-authors include Bradley J. Monk, John P. Fruehauf, Jeremy D. Bartos, Dana M. Chase, Seiichi Matsui, Lindsey E. Minion, Robert A. Bambara, Sheila Sait, Nicholas J. Petrelli and Garth R. Anderson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Lyndsay Willmott

31 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lyndsay Willmott United States	10	136	129	120	106	58	36	381
Aki Miyasaka Japan	14	282 2.1×	113 0.9×	74 0.6×	101 1.0×	119 2.1×	18	473
Kanako Inaba Japan	10	170 1.3×	77 0.6×	37 0.3×	48 0.5×	83 1.4×	13	306
Xiaohua Wu China	3	174 1.3×	122 0.9×	97 0.8×	53 0.5×	133 2.3×	3	407
Jole Ventriglia Italy	13	111 0.8×	369 2.9×	52 0.4×	83 0.8×	125 2.2×	36	547
Weiya Z. Wysham United States	12	222 1.6×	133 1.0×	78 0.7×	76 0.7×	137 2.4×	23	467
J Belotte United States	10	107 0.8×	83 0.6×	43 0.4×	78 0.7×	39 0.7×	19	316
Xuan Jiang China	9	186 1.4×	252 2.0×	18 0.1×	104 1.0×	53 0.9×	17	464
Xiujie Sheng China	10	292 2.1×	61 0.5×	56 0.5×	44 0.4×	227 3.9×	24	454
Yanping Zhong China	14	161 1.2×	172 1.3×	15 0.1×	59 0.6×	83 1.4×	37	476
Salah T. Fayed Egypt	8	120 0.9×	111 0.9×	45 0.4×	84 0.8×	57 1.0×	16	337

Countries citing papers authored by Lyndsay Willmott

Since Specialization

Citations

This map shows the geographic impact of Lyndsay Willmott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lyndsay Willmott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lyndsay Willmott more than expected).

Fields of papers citing papers by Lyndsay Willmott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lyndsay Willmott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lyndsay Willmott. The network helps show where Lyndsay Willmott may publish in the future.

Co-authorship network of co-authors of Lyndsay Willmott

This figure shows the co-authorship network connecting the top 25 collaborators of Lyndsay Willmott. A scholar is included among the top collaborators of Lyndsay Willmott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lyndsay Willmott. Lyndsay Willmott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, John K., June‐Yong Lee, Mariana Scaranti, et al.. (2025). LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor. Annals of Oncology. 36. S1588–S1589.

Cloven, Noelle, Ira Winer, Eric Lee, et al.. (2025). 1121P Rinatabart sesutecan (Rina-S®) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL™-01. Annals of Oncology. 36. S700–S700.

Le, Ngoc‐Anh, et al.. (2025). Outpatient hybrid intracavitary-interstitial brachytherapy for cervical cancer with minimal sedation in a freestanding setting. Gynecologic Oncology Reports. 59. 101767–101767.

Jørgensen, Trine Lembrecht, Destin Black, David Cibula, et al.. (2024). Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. 42(16_suppl). 5607–5607. 1 indexed citations

Łaniewski, Paweł, Haiyan Cui, Nichole D. Mahnert, et al.. (2024). Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification. Clinical Cancer Research. 30(14). 3073–3087. 5 indexed citations

Auranen, Annika, Lyndsay Willmott, David Cibula, et al.. (2024). 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups. ESMO Open. 9. 103537–103537. 3 indexed citations

Corr, Bradley R., Ecaterina E. Dumbrava, Alexander I. Spira, et al.. (2024). 733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03. Annals of Oncology. 35. S558–S558. 1 indexed citations

Powell, Matthew A., Annika Auranen, Lyndsay Willmott, et al.. (2024). Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial. Gynecologic Oncology. 190. S4–S5. 5 indexed citations

Santin, Alessandro D., Bradley R. Corr, Alexander I. Spira, et al.. (2024). Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 42(29). 3421–3429. 20 indexed citations

10.

Slomovitz, Brian M., Robert L. Coleman, Lucy Gilbert, et al.. (2023). 750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S514–S515. 2 indexed citations

11.

Mirza, Mansoor Raza, Mark S. Shahin, Matthew A. Powell, et al.. (2023). Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.. JCO Oncology Practice. 19(11_suppl). 332–332. 1 indexed citations

12.

Farley, John, et al.. (2023). Robotic-assisted gynecologic surgery in an older population: A comparison study. Journal of Geriatric Oncology. 14(6). 101533–101533. 2 indexed citations

13.

Oaknin, Ana, Rebecca Kristeleit, Myong Cheol Lim, et al.. (2022). 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). International Journal of Gynecological Cancer. 32. A472–A472. 1 indexed citations

14.

Łaniewski, Paweł, Haiyan Cui, Nichole D. Mahnert, et al.. (2022). Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. Biomarker Research. 10(1). 88–88. 9 indexed citations

15.

Chase, Dana M., Margarita Romeo, Floor Backes, et al.. (2022). Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial. Gynecologic Oncology. 166(3). 494–502. 10 indexed citations

16.

Moore, Kathleen N., Michael A. Bookman, Jalid Sehouli, et al.. (2020). LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). Annals of Oncology. 31. S1161–S1162. 28 indexed citations

17.

Minion, Lindsey E., Dana M. Chase, John Farley, Lyndsay Willmott, & Bradley J. Monk. (2016). Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study. PubMed. 3(1). 4–4. 9 indexed citations

18.

Willmott, Lyndsay, et al.. (2010). Biologics in Cervical Cancer Therapy. Journal of the National Comprehensive Cancer Network. 8(12). 1417–1423. 1 indexed citations

19.

Bartos, Jeremy D., Lyndsay Willmott, Sara K. Binz, Marc S. Wold, & Robert A. Bambara. (2008). Catalysis of Strand Annealing by Replication Protein A Derives from Its Strand Melting Properties. Journal of Biological Chemistry. 283(31). 21758–21768. 13 indexed citations

20.

Bartos, Jeremy D., Daniel L. Stoler, Seiichi Matsui, et al.. (2004). Genomic heterogeneity and instability in colorectal cancer: spectral karyotyping, glutathione transferase-Ml and ras. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 568(2). 283–292. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact